Immunic (NASDAQ:IMUX) Receives Buy Rating from HC Wainwright

HC Wainwright reaffirmed their buy rating on shares of Immunic (NASDAQ:IMUX) in a research note issued to investors on Monday morning,Benzinga reports. The firm currently has a $8.00 price objective on the stock.

Other analysts also recently issued reports about the company. Weiss Ratings restated a “sell (e+)” rating on shares of Immunic in a report on Monday, December 29th. Brookline Cap M raised shares of Immunic to a “strong-buy” rating in a research report on Tuesday, February 3rd. Chardan Capital raised shares of Immunic to a “strong-buy” rating in a research report on Wednesday, November 19th. D. Boral Capital reiterated a “buy” rating and set a $8.00 price objective on shares of Immunic in a research note on Wednesday, January 7th. Finally, Roth Mkm started coverage on shares of Immunic in a research note on Friday, November 7th. They issued a “buy” rating and a $3.00 price objective for the company. Four investment analysts have rated the stock with a Strong Buy rating, five have assigned a Buy rating and one has given a Sell rating to the stock. According to data from MarketBeat, the company currently has a consensus rating of “Buy” and an average target price of $7.40.

Immunic Stock Performance

Shares of NASDAQ IMUX opened at $0.71 on Monday. Immunic has a 52-week low of $0.51 and a 52-week high of $1.39. The firm has a market capitalization of $85.29 million, a price-to-earnings ratio of -0.85 and a beta of 1.58. The stock has a 50 day moving average price of $0.63 and a 200 day moving average price of $0.77.

Immunic (NASDAQ:IMUX) last released its quarterly earnings data on Thursday, November 13th. The company reported ($0.13) EPS for the quarter, topping the consensus estimate of ($0.18) by $0.05. Analysts forecast that Immunic will post -0.94 earnings per share for the current year.

Institutional Investors Weigh In On Immunic

A number of hedge funds and other institutional investors have recently bought and sold shares of IMUX. Aberdeen Group plc grew its holdings in Immunic by 678.1% in the second quarter. Aberdeen Group plc now owns 8,243,941 shares of the company’s stock worth $5,750,000 after purchasing an additional 7,184,457 shares during the last quarter. Geode Capital Management LLC boosted its position in shares of Immunic by 13.8% in the 4th quarter. Geode Capital Management LLC now owns 1,176,285 shares of the company’s stock worth $628,000 after purchasing an additional 142,513 shares in the last quarter. Millennium Management LLC boosted its position in shares of Immunic by 414.5% in the 3rd quarter. Millennium Management LLC now owns 530,470 shares of the company’s stock worth $468,000 after purchasing an additional 427,361 shares in the last quarter. Focus Partners Wealth grew its stake in Immunic by 1.5% during the 3rd quarter. Focus Partners Wealth now owns 2,581,587 shares of the company’s stock worth $2,276,000 after buying an additional 39,063 shares during the last quarter. Finally, Squarepoint Ops LLC acquired a new position in Immunic during the 3rd quarter valued at about $239,000. Hedge funds and other institutional investors own 51.82% of the company’s stock.

About Immunic

Immunic, Inc is a clinical-stage biopharmaceutical company focused on developing novel oral therapies to treat chronic inflammatory and autoimmune diseases as well as certain cancers. The company’s research strategy centers on small-molecule immunology, aiming to offer targeted treatments with improved safety and tolerability profiles. By modulating key signaling pathways within the immune system, Immunic seeks to address underlying disease mechanisms and achieve durable therapeutic benefits for patients.

Immunic’s lead product candidate, vidofludimus calcium (IMU-838), is an oral selective dihydroorotate dehydrogenase (DHODH) inhibitor in Phase 2 clinical development for conditions including ulcerative colitis, Crohn’s disease and relapsing multiple sclerosis.